Company receives notice from FDA for not fully investigating foreign particles in APIs and finished products made from its facility in Ingelheim am Rhein, Germany. FDA issued a Warning Letter to ...
INGELHEIM AM RHEIN, Germany & GENEVA--(BUSINESS WIRE)--Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback